MEI Pharma Reports Q3 GAAP EPS of -$0.39, Cash and Cash Equivalents at $20.5 Million

MEI Pharma reported Q3 GAAP EPS of -$0.39. The company had $20.5 million in cash and cash equivalents as of March 31, 2025, with no outstanding debt.

MEI Pharma, Inc. (Nasdaq: MEIP) reported its third-quarter fiscal year 2025 earnings, showing a GAAP EPS of -$0.39. Despite the loss, the company maintains a robust cash position with $20.5 million in cash and cash equivalents as of March 31, 2025, and no outstanding debt [1].

The company continues to evaluate potential strategic alternatives, including out-licensing opportunities for existing programs and merger and acquisition prospects, with the aim of maximizing shareholder value. Oppenheimer & Co., Inc. serves as the exclusive financial advisor in this process [2].

MEI Pharma's cash preservation efforts have included a reduction-in-force, which is progressing in stages as the company's operational and strategic direction evolves. The company does not expect to disclose developments related to these strategic alternatives unless or until the evaluation process is completed or the Board of Directors deems it appropriate [2].

The company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which holds promise for novel and differentiated cancer therapies. For more information, visit [MEI Pharma's website](www.meipharma.com) [3].

References:
[1] https://seekingalpha.com/news/4447630-mei-pharma-gaap-eps-of-0_39
[2] https://www.marketscreener.com/quote/stock/MEI-PHARMA-INC-12212540/news/MEI-Pharma-Reports-Third-Quarter-Fiscal-Year-2025-Cash-Position-49935174/
[3] https://finance.yahoo.com/news/mei-pharma-reports-third-quarter-200500270.html